Cargando…
Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
Chemotherapeutic treatment of breast cancer is based on maximum tolerated dose (MTD) approach. However, advanced stage tumors are not effectively eradicated by MTD owing to suboptimal drug targeting, onset of therapeutic resistance and neoangiogenesis. In contrast, “metronomic” chemotherapy is based...
Autores principales: | Mazzucchelli, Serena, Bellini, Michela, Fiandra, Luisa, Truffi, Marta, Rizzuto, Maria A., Sorrentino, Luca, Longhi, Erika, Nebuloni, Manuela, Prosperi, Davide, Corsi, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352408/ https://www.ncbi.nlm.nih.gov/pubmed/28039473 http://dx.doi.org/10.18632/oncotarget.14204 |
Ejemplares similares
-
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
por: Mazzucchelli, S., et al.
Publicado: (2017) -
Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
por: Sitia, Leopoldo, et al.
Publicado: (2021) -
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model
por: Andreata, F., et al.
Publicado: (2020) -
Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review
por: Mainini, Francesco, et al.
Publicado: (2021) -
Novel Bioengineering
Strategies to Improve Bioavailability
and In Vivo Circulation of H-Ferritin Nanocages
by Surface Functionalization
por: Sevieri, Marta, et al.
Publicado: (2023)